Online citations, reference lists, and bibliographies.
← Back to Search

Particles And Powders: Tools Of Innovation For Non-invasive Drug Administration.

F. Buttini, P. Colombo, A. Rossi, F. Sonvico, G. Colombo
Published 2012 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The paper briefly illustrates several approaches applied in delivering particulate drugs as powders. Microparticulate drug powders are difficult to manipulate with respect to dosage form preparation, particularly when they have very small size as this leads to poor flow and packing properties. When the dosage form performance resides in the presence of individual intact drug particles, the particle characteristics have to be retained in their original state, i.e., not altered during manufacturing and/or within the dosage form. There are several examples of dry powder dosage forms intended for different administration routes whose performance is strictly dependent on particle characteristics. In addition, the preparation of the finished dosage form is dependent on powder properties. The paper addresses dry powder formulations with special focus on oral powders mainly for elderly people or children, nasal powders and inhalation dry powders. These dosage forms are very attractive for both researchers and companies. Their formulation requires deep investigation, mainly in order to define particle structure and performance. Indeed, this makes for a new breakthrough in pharmaceutics and may lead to innovative products.
This paper references
10.1016/j.ijpharm.2010.08.045
Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
Martin J. Donovan (2010)
10.1016/j.jconrel.2010.08.007
Cyclodextrin complexed insulin encapsulated hydrogel microparticles: An oral delivery system for insulin.
S. Sajeesh (2010)
10.1517/17425247.2011.610304
Spray granulation for drug formulation
Z. H. Loh (2011)
10.1016/j.ijpharm.2011.09.043
Layered lipid microcapsules for mesalazine delayed-release in children.
A. G. Balducci (2011)
10.1016/S0378-5173(01)00736-0
Improved nasal bioavailability of elcatonin by insoluble powder formulation.
F. Ishikawa (2001)
10.1208/pt050460
The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer
F. Ferrari (2008)
10.1021/JS960500J
Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits.
E. Marttin (1997)
10.1080/03639040802235902
Advancements in Dry Powder Delivery to the Lung
Yoen-Ju Son (2008)
10.1016/J.ADDR.2005.07.009
Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives.
M. I. Ugwoke (2005)
10.1016/j.ijpharm.2010.10.003
Extrusion-spheronisation of highly loaded 5-ASA multiparticulate dosage forms.
G. Di Pretoro (2010)
10.1016/S0378-5173(02)00177-1
Caffeine microparticles for nasal administration obtained by spray drying.
C. Sacchetti (2002)
10.1016/j.yexmp.2008.12.004
Nanoparticle-based targeted drug delivery.
R. Singh (2009)
Nanoparticulate carriers (NPC) for oral pharmaceutics and nutraceutics.
C. M. Lopes (2010)
10.1016/S0378-5173(00)00347-1
The influence of carrier morphology on drug delivery by dry powder inhalers.
Xiao Mei Zeng (2000)
10.1016/j.tube.2010.03.005
The near future: improving the activity of rifamycins and pyrazinamide.
D. Mitchison (2010)
10.1016/j.ijpharm.2009.07.008
Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine.
P. Hiremath (2009)
10.1016/S1773-2247(07)50081-X
Soft agglomerates of pantoprazole gastro-resistant microparticles for oral administration and intestinal release
R. Raffin (2007)
10.1016/j.ijpharm.2009.11.035
Self-assembled cyclodextrin aggregates and nanoparticles.
M. Messner (2010)
10.18433/J3NC79
Intranasal drug delivery: how, why and what for?
A. Pires (2009)
10.1016/S0939-6411(03)00090-0
Pediatric drug formulations of sodium benzoate
J. Breitkreutz (2003)
10.1358/dnp.2010.23.7.1458283
If children ruled the pharmaceutical industry: the need for pediatric formulations.
M. Rieder (2010)
10.1007/s00280-011-1798-2
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study
S. DuBois (2011)
10.1002/jps.22054
Delivery of therapeutic proteins.
D. Pisal (2010)
10.1016/j.ejps.2010.04.012
Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders.
Qi (Tony) Zhou (2010)
10.1002/JPS.20604
Primary microparticles and agglomerates of morphine for nasal insufflation.
P. Russo (2006)
10.1016/j.antiviral.2011.09.012
Brain distribution of ribavirin after intranasal administration.
G. Colombo (2011)
10.1016/S1773-2247(06)50061-9
Chitosan nanocapsules: a new carrier for nasal peptide delivery
C. Prego (2006)
10.1016/J.IJPHARM.2003.11.001
Theophylline particle design using chitosan by the spray drying.
Mayumi Asada (2004)
10.1007/s11095-007-9475-1
Pharmaceutical Particle Engineering via Spray Drying
R. Vehring (2007)
10.1002/JPS.21101
Pediatric drugs--a review of commercially available oral formulations.
R. Strickley (2008)
10.1016/j.ejpb.2009.11.015
Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles.
R. Raffin (2010)
10.1016/j.ijpharm.2011.12.045
A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles.
Y. Wang (2012)
10.2147/IJN.S20353
Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery
X. Li (2011)
10.2174/187221111797200588
Powdered lipid nano and microparticles: production and applications.
Amandine Berton (2011)
10.3109/02652048.2011.590613
Gastroretentive microparticles for drug delivery applications
Adeola O. Adebisi (2011)
10.1007/s11095-006-9174-3
Particle Engineering for Pulmonary Drug Delivery
Albert H. L. Chow (2006)
10.1517/17425247.2012.647907
Excipients with specialized functions for effective drug delivery
J. Hamman (2012)
10.1016/S1773-2247(04)50083-7
Chimeral agglomerates of microparticles for the administration of caffeine nasal powders
P. Russo (2004)
10.1016/j.ejpb.2011.12.004
Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
V. N. Le (2012)
10.1016/j.ejpb.2011.02.005
Orally disintegrating mini-tablets (ODMTs)--a novel solid oral dosage form for paediatric use.
I. Stoltenberg (2011)
10.1016/j.ijpharm.2008.04.044
Dry powder inhalers (DPIs)--a review of device reliability and innovation.
N. Islam (2008)
10.2165/11539070-000000000-00000
Systemic and Mucosal Delivery of Drugs within Polymeric Microparticles Produced by Spray Drying
K. Bowey (2012)
10.1007/s00125-001-0751-z
Self-assembled “nanocubicle” as a carrier for peroral insulin delivery
H. Chung (2001)
10.1016/j.ijpharm.2009.04.038
Advantages of celecoxib nanosuspension formulation and transformation into tablets.
Andrej Dolenc (2009)
10.1016/J.EJPB.2007.04.004
Oral low molecular weight heparin delivery by microparticles from complex coacervation.
A. Lamprecht (2007)
10.1007/s11095-007-9466-2
Core–shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants
Libo Wu (2007)
10.1002/JPS.21126
Back to basics: the development of a simple, homogenous, two-component dry-powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers.
F. Buttini (2008)
10.1208/s12249-011-9582-5
Towards Integrated Drug Substance and Drug Product Design for an Active Pharmaceutical Ingredient Using Particle Engineering
E. Kougoulos (2011)
10.1016/j.socscimed.2009.08.024
Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes.
S. Craig (2009)
10.1159/000321044
Nasal drug delivery in humans.
Christoph Bitter (2011)
10.1089/JAM.2004.17.249
Bi-directional nasal delivery of aerosols can prevent lung deposition.
P. Djupesland (2004)
10.1016/j.ejpb.2011.03.024
Development of potential novel cushioning agents for the compaction of coated multi-particulates by co-processing micronized lactose with polymers.
X. Lin (2011)
10.1007/s11095-011-0412-y
Self-Assembled and Nanostructured siRNA Delivery Systems
J. Jeong (2011)
10.1089/jamp.2010.0855
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
D. Geller (2011)
10.1016/S0169-409X(97)00064-1
Optimization of systemic nasal drug delivery with pharmaceutical excipients.
Roméo (1998)
10.1016/j.ijpharm.2011.05.079
Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability.
M. A. Alhnan (2011)
10.1016/S0378-5173(98)00300-7
The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro
Xian Ming Zeng (1998)
10.1208/s12249-011-9690-2
Advanced Technologies for Oral Controlled Release: Cyclodextrins for Oral Controlled Release
P. Salústio (2011)
10.1016/j.ijpharm.2009.10.032
Novel pMDI formulations for pulmonary delivery of proteins.
Hao-ying Li (2010)
10.1016/j.colsurfb.2010.04.016
Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
Waseem Kaialy (2010)
10.1016/S0928-0987(00)00087-7
Transport of drugs from the nasal cavity to the central nervous system.
L. Illum (2000)
10.1016/j.addr.2011.03.011
Production methods for nanodrug particles using the bottom-up approach.
H. Chan (2011)
10.1016/S0169-409X(01)00171-5
Chitosan as a novel nasal delivery system for vaccines.
L. Illum (2001)
10.1016/S0169-409X(97)00507-3
Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations.
Buckton (1997)
10.1016/J.IJPHARM.2005.10.049
Influence of deposition and spray pattern of nasal powders on insulin bioavailability.
E. Pringels (2006)
10.1177/0333102409359314
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study
P. Djupesland (2010)
10.2165/00003088-200342130-00003
Absorption Enhancers for Nasal Drug Delivery
S. Davis (2003)
10.1002/DMRR.207
Development of oral insulin: progress and current status.
J. Still (2002)
10.1517/17425247.2011.598147
Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations
P. Srinarong (2011)
10.1023/A:1019881706159
Insoluble Powder Formulation as an Effective Nasal Drug Delivery System
F. Ishikawa (2004)
10.1615/CRITREVTHERDRUGCARRIERSYST.V17.I3.10
New approaches to antigen delivery.
D. Fitzgerald (2000)
10.1002/smll.201100442
More effective nanomedicines through particle design.
J. Wang (2011)
10.1016/S0939-6411(03)00091-2
Pediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder.
J. Breitkreutz (2003)
10.1002/JPS.20718
Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?
L. Illum (2007)
10.1080/03639040802698794
Influence of carrier surface fines on dry powder inhalation formulations
Antesar M Boshhiha (2009)
10.1016/j.ijpharm.2010.11.020
Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability.
S. Kim (2011)
10.4193/RHIN09.178
Preliminary efficacy of fluticasone delivered by a novel device in recalcitrant chronic rhinosinusitis.
Hansen Fs (2010)
10.2337/DIACARE.26.2.421
Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
M. Kipnes (2003)
10.1016/S0378-5173(01)00873-0
In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits.
S. T. Lim (2002)
10.1016/S0169-409X(97)00067-7
Nasal delivery systems and their effect on deposition and absorption.
Vidgren (1998)
10.1016/j.ijpharm.2011.01.027
Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy?
V. Tran (2011)
10.1248/CPB.52.350
Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
K. Iida (2004)
10.1016/j.peptides.2009.10.002
Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery
M. Tan (2010)
10.1007/s11095-009-9871-9
Clinical Study Shows Improved Absorption of Desmopressin with Novel Formulation
N. Fransén (2009)



This paper is referenced by
10.3109/10837450.2016.1163387
Influence of different surfactants on the physicochemical properties of elastic liposomes
R. M. Barbosa (2017)
10.1016/j.ejpb.2015.03.023
Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation.
S. Belotti (2015)
10.1080/10717544.2018.1428242
In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates
A. Giuliani (2018)
10.1080/03639045.2019.1652636
Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction
J. Kozáková (2019)
Development of multifunctional composite aerosols for lung cancer therapy
Marta Chaves Silva (2016)
10.3109/02652048.2015.1134687
Opioid-based micro and nanoparticulate formulations: alternative approach on pain management
André São Pedro (2016)
10.1517/17425247.2015.980812
Solid lipid microparticles as an approach to drug delivery
S. Scalia (2015)
10.1016/j.ijpharm.2014.01.033
Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.
F. Buttini (2014)
DRUG DELIVERY SYSTEMS
Giulia Auriemma (2013)
10.1016/j.ejps.2020.105574
Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations.
Benedict Benque (2020)
10.14273/UNISA-821
Chronotherapeutic Drug Delivery in Early Morning Pathologies: Design and Production of new NSAIDs/SAIDs polysaccharide-based systems
Andrea Cerciello (2017)
10.1016/j.powtec.2020.10.061
Microfluidic spray dried and spray freeze dried uniform microparticles potentially for intranasal drug delivery and controlled release
Aijun Di (2020)
10.1016/j.ijpharm.2014.05.055
Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction.
S. Belotti (2014)
10.1016/j.ejps.2011.03.005
Novel dry powder inhalation system based on dispersion of lyophilisates.
Sarah Claus (2011)
10.1016/j.powtec.2019.11.029
Lecithin-based modified soft agglomerate composite microparticles for inhalable montelukast: Development, tolerability and pharmacodynamic activity
Roxane Abdel-Gawad (2020)
Development of composite particles for pulmonary delivery
Márcia T. Tavares (2014)
10.1002/9781118799536.CH11
Drug Delivery Strategies for Pulmonary Administration of Antibiotics
Anna Giulia Balducci (2015)
10.1016/j.ijpharm.2019.02.018
Effects of the antibiotic component on in‐vitro bacterial killing, physico‐chemical properties, aerosolization and dissolution of a ternary‐combinational inhalation powder formulation of antibiotics for pan‐drug resistant Gram‐negative lung infections
S. Mangal (2019)
10.1016/J.POWTEC.2015.02.001
Polymeric microparticles containing indomethacin for inhalatory administration
N. E. Ceschan (2015)
10.1016/j.ijpharm.2015.09.052
Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide.
Gilles Dufour (2015)
Development of chitosan-based microparticles for pulmonary drug delivery
Grau de Mestre (2013)
10.1080/1061186X.2019.1574300
Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease
Laura Tiozzo Fasiolo (2019)
10.1007/s11095-016-1887-3
Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling
Yoshiki Seto (2016)
10.1016/j.msec.2014.04.040
New alginic acid-atenolol microparticles for inhalatory drug targeting.
N. E. Ceschan (2014)
10.1007/s11095-017-2334-9
Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation
S. Mangal (2017)
10.3390/pharmaceutics12070669
Nanosystems for the Encapsulation of Natural Products: The Case of Chitosan Biopolymer as a Matrix
Anastasia Detsi (2020)
10.1016/J.JDDST.2015.07.010
High shear mixing of lactose and salmeterol xinafoate dry powder blends: Biopharmaceutic and aerodynamic performances
Anna Giulia Balducci (2015)
Pharmaceutical Nanotechnologies: Lecithin/Chitosan Nanoparticles
G. Colombo (2015)
10.1155/2018/5635010
Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering
P. Mehta (2018)
10.1016/j.ejpb.2016.07.003
Alginate-based hybrid aerogel microparticles for mucosal drug delivery.
V. S. Gonçalves (2016)
10.1016/j.ejps.2017.09.027
Opportunity and challenges of nasal powders: Drug formulation and delivery
L. T. Fasiolo (2018)
10.1089/jamp.2015.1220
Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler® in Comparison with Diskus® and Turbohaler® Dry Powder Inhalers
F. Buttini (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar